Literature DB >> 2146293

Management of onychomycosis with oral terbinafine.

N Zaias1.   

Abstract

The safety and efficacy of oral terbinafine in the treatment of finger onychomycosis caused by Trichophyton rubrum were evaluated in an open study including 11 patients. Treatment consisted of 125 mg of terbinafine given twice daily for 6 months or until the infection cleared. At the end of the treatment period, all patients were clinically and mycologically normal, with the drug acting as a fungal barrier to prevent further distal fungal invasion into the nailplate. Mild gastric discomfort in one patient was the only side effect reported during this study. No laboratory abnormalities were detected.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2146293     DOI: 10.1016/0190-9622(90)70295-s

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  5 in total

Review 1.  Adverse drug reactions to systemic antifungals. Prevention and management.

Authors:  J R Perfect; M H Lindsay; R H Drew
Journal:  Drug Saf       Date:  1992 Sep-Oct       Impact factor: 5.606

Review 2.  Clinical and economic factors in the treatment of onychomycosis.

Authors:  T R Einarson; A K Gupta; N H Shear; S Arikian
Journal:  Pharmacoeconomics       Date:  1996-04       Impact factor: 4.981

Review 3.  Terbinafine. A pharmacoeconomic evaluation of its use in superficial fungal infections.

Authors:  R Davis; J A Balfour
Journal:  Pharmacoeconomics       Date:  1995-09       Impact factor: 4.981

4.  Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toenails. A US analysis.

Authors:  A K Gupta
Journal:  Pharmacoeconomics       Date:  1998-02       Impact factor: 4.981

5.  Quality of life of persons with onychomycosis.

Authors:  D P Lubeck; D L Patrick; P McNulty; S K Fifer; J Birnbaum
Journal:  Qual Life Res       Date:  1993-10       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.